Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Pacira Pharmaceuticals (PCRX) PT Raised to $46 at Mizuho Securities Following 3Q
November 5, 2018 7:16 AM ESTMizuho Securities analyst Irina Koffler raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $46.00 (from $43.00) while maintaining a Neutral rating following the company's 3Q earnings report. Mizuho Securities raised 2018 Exparel sales to $331.8M (from $321.2M) and 2019 estimates to $396.5M (from $376.8M prior); both above... More
